Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KPTI Karyopharm Therapeutics	$5.62 -5.9%	$5.91	$3.51 ▼ $18.00	$48.16M	0.58	82,347 shs	50,896 shs
MURA Mural Oncology	$2.60 -1.5%	$2.71	$0.95 ▼ $4.74	$44.79M	5.28	1.30 million shs	434,657 shs
NERV Minerva Neurosciences	$1.78 +1.7%	$1.63	$1.15 ▼ $3.69	$12.45M	-0.09	28,670 shs	5,572 shs
QNCX Quince Therapeutics	$1.23 +9.3%	$1.28	$0.51 ▼ $2.45	$54.27M	0.74	247,585 shs	45,680 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KPTI Karyopharm Therapeutics	0.00%	+13.54%	+35.10%	-45.38%	-64.65%
MURA Mural Oncology	0.00%	-3.70%	+120.34%	-33.16%	-27.37%
NERV Minerva Neurosciences	0.00%	+11.25%	-1.66%	-24.89%	-26.94%
QNCX Quince Therapeutics	0.00%	+24.18%	-8.89%	-28.49%	+16.04%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
KPTI Karyopharm Therapeutics	3.4574 of 5 stars	3.5	0.0	4.6	1.0	2.5	0.6
MURA Mural Oncology	3.0485 of 5 stars	3.3	5.0	0.0	1.7	1.7	1.3
NERV Minerva Neurosciences	3.5883 of 5 stars	3.0	5.0	4.6	1.8	0.0	0.0
QNCX Quince Therapeutics	2.8191 of 5 stars	3.6	3.0	0.0	2.7	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KPTI Karyopharm Therapeutics	3.00	Buy	$57.50	923.13% Upside
MURA Mural Oncology	2.60	Moderate Buy	$13.00	400.00% Upside
NERV Minerva Neurosciences	2.00	Hold	$5.00	180.90% Upside
QNCX Quince Therapeutics	3.29	Buy	$8.00	550.41% Upside

Current Analyst Ratings Breakdown

Latest NERV, MURA, QNCX, and KPTI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/26/2025	MURA Mural Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $6.00
3/25/2025	MURA Mural Oncology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight
3/25/2025	MURA Mural Oncology	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform	$18.00
3/25/2025	MURA Mural Oncology	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
3/25/2025	QNCX Quince Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $4.00
3/24/2025	QNCX Quince Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$10.00
3/12/2025	MURA Mural Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
3/3/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$75.00 ➝ $54.00
2/26/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $56.00
2/26/2025	NERV Minerva Neurosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$5.00 ➝ $5.00
2/20/2025	KPTI Karyopharm Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$45.00 ➝ $45.00

(Data available from 4/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KPTI Karyopharm Therapeutics	$145.24M	0.33	N/A	N/A	($1.47) per share	-3.82
MURA Mural Oncology	N/A	N/A	N/A	N/A	$15.81 per share	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	($4.07) per share	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	$1.98 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KPTI Karyopharm Therapeutics	-$143.10M	-$15.29	N/A	N/A	N/A	-52.62%	N/A	-39.58%	5/6/2025 (Estimated)
MURA Mural Oncology	-$207.45M	-$7.58	N/A	N/A	N/A	N/A	-70.10%	-61.30%	5/13/2025 (Estimated)
NERV Minerva Neurosciences	-$30M	$0.19	N/A	N/A	N/A	N/A	N/A	-6.74%	4/29/2025 (Estimated)
QNCX Quince Therapeutics	-$31.39M	-$1.31	N/A	N/A	N/A	N/A	-53.27%	-22.73%	5/12/2025 (Estimated)

Latest NERV, MURA, QNCX, and KPTI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	KPTI Karyopharm Therapeutics	-$4.21	N/A	N/A	N/A	$35.12 million	N/A
5/13/2025	N/A	MURA Mural Oncology	-$1.68	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	QNCX Quince Therapeutics	-$0.24	N/A	N/A	N/A	N/A	N/A
5/7/2025	Q1 2025	NERV Minerva Neurosciences	-$1.07	N/A	N/A	N/A	N/A	N/A
3/24/2025	Q4 2024	QNCX Quince Therapeutics	-$0.19	-$0.28	-$0.09	-$0.28	N/A	$0.17 million
3/11/2025	Q4	MURA Mural Oncology	-$1.96	-$2.01	-$0.05	-$2.01	N/A	N/A
2/27/2025	Q4 2024	NERV Minerva Neurosciences	-$1.05	-$0.56	+$0.49	-$0.56	N/A	N/A
2/19/2025	Q4 2024	KPTI Karyopharm Therapeutics	-$3.90	-$3.60	+$0.30	-$0.24	$30.29 million	$30.54 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A
MURA Mural Oncology	N/A	N/A	N/A	N/A	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KPTI Karyopharm Therapeutics	N/A	1.70	2.93
MURA Mural Oncology	N/A	7.38	7.38
NERV Minerva Neurosciences	N/A	6.23	6.23
QNCX Quince Therapeutics	0.33	9.53	9.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KPTI Karyopharm Therapeutics	66.44%
MURA Mural Oncology	80.21%
NERV Minerva Neurosciences	34.56%
QNCX Quince Therapeutics	30.75%

Insider Ownership

Company	Insider Ownership
KPTI Karyopharm Therapeutics	2.75%
MURA Mural Oncology	0.06%
NERV Minerva Neurosciences	8.60%
QNCX Quince Therapeutics	16.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KPTI Karyopharm Therapeutics	380	8.57 million	122.72 million	Optionable
MURA Mural Oncology	119	17.23 million	17.01 million	Optionable
NERV Minerva Neurosciences	9	6.99 million	6.39 million	Not Optionable
QNCX Quince Therapeutics	60	44.12 million	36.61 million	Optionable

NERV, MURA, QNCX, and KPTI Headlines

Recent News About These Companies

Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference

April 3, 2025 | businesswire.com

Quince Therapeutics (QNCX) Expected to Announce Earnings on Monday

March 31, 2025 | marketbeat.com

Quince Therapeutics, Inc. (NASDAQ:QNCX) Short Interest Down 33.5% in March

March 30, 2025 | marketbeat.com

Analysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD)

March 27, 2025 | markets.businessinsider.com

Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results

March 24, 2025 | businesswire.com

Oppenheimer Initiates Coverage of Quince Therapeutics (QNCX) with Outperform Recommendation

March 24, 2025 | msn.com

Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

February 7, 2025 | businesswire.com

Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 5, 2025 | businesswire.com

Quince Therapeutics gets USPTO notice of allowance in Ataxia-Telangiectasia

February 4, 2025 | markets.businessinsider.com

Quince Therapeutics secures USPTO nod for A-T treatment patent

February 4, 2025 | msn.com

Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia

February 4, 2025 | businesswire.com

Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia

January 27, 2025 | finance.yahoo.com

Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board

January 24, 2025 | finance.yahoo.com

Quince Therapeutics initiated with a Buy at Brookline

December 19, 2024 | msn.com

Brookline Capital Initiates Coverage of Quince Therapeutics (QNCX) with Buy Recommendation

December 19, 2024 | msn.com

Quince Therapeutics Share Price (QNCX.US)

November 18, 2024 | lse.co.uk

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

November 13, 2024 | businesswire.com

Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research

November 13, 2024 | finance.yahoo.com

Quince Therapeutics presents safety data from ATTeST trial at CNS meeting

November 13, 2024 | markets.businessinsider.com

Quince Therapeutics presents data from prior Phase 3 ATTeST clinical trial

November 13, 2024 | markets.businessinsider.com

Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting

November 11, 2024 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NERV, MURA, QNCX, and KPTI Company Descriptions

Karyopharm Therapeutics NASDAQ:KPTI

$5.62 -0.35 (-5.86%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$5.76 +0.14 (+2.49%)

As of 04/25/2025 07:22 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Mural Oncology NASDAQ:MURA

$2.60 -0.04 (-1.52%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$2.64 +0.03 (+1.35%)

As of 04/25/2025 07:46 PM Eastern

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.

Minerva Neurosciences NASDAQ:NERV

$1.78 +0.03 (+1.71%)

Closing price 04/25/2025 03:53 PM Eastern

Extended Trading

$1.79 +0.01 (+0.56%)

As of 04/25/2025 06:54 PM Eastern

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Quince Therapeutics NASDAQ:QNCX

$1.23 +0.11 (+9.33%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$1.19 -0.04 (-3.25%)

As of 04/25/2025 07:42 PM Eastern

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time